Again the corollary to anticoagulant therapy is risk of bleeding, and the Figure shows the curves for major bleeding events with apixaban.[99] Apixaban was clearly superior to warfarin for this result, with a risk reduction of 31% (p<0.001).  This stands in contrast to rivaroxaban and dabigatran, where the risk of major bleeding was similar to that with warfarin.

 Reiffel JA. Am J Med 2013; 126: 00-00.